Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05438225 · ClinicalTrials.gov registry record · NA

Text Message Reminders for Hearing Healthcare

A NA study, sponsored by Stanford University.

Completed
Registry status
NA
Development phase
41
Enrollment target

NCT05438225: Completed NA study, sponsored by Stanford University.

NCT05438225 is a NA study that has completed, run by Stanford University. The registered enrollment target is 41 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (97% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist → Add completion date to calendar (.ics) →

The verdict

NCT05438225, a NA study, has completed, sponsored by Stanford University.

COMPLETED
Registry status
NA
Development phase
41 participants
Enrollment target

Study Summary

Many individuals with hearing loss do not receive adequate hearing healthcare. Given their close and long-term relationships with patients, primary care providers (PCPs) could play a vital role in improving access to hearing healthcare. Unfortunately, hearing loss is often underdiagnosed in primary care settings, because hearing screening is not a routine part of primary care visits, and the responsibility often falls on the patient or family to recognize and address the issue. The investigators propose to pilot test the use of text message reminders to encourage elderly patients to discuss hearing assessment with there PCPs. The study objectives are to: 1) design an automated text-messaging reminder system; 2) assess the feasibility of deploying the intervention in a clinical trial setting; and 3) evaluate whether the intervention increases willingness to seek hearing healthcare.

Primary Outcome

Participant-reported rating of the likelihood of discussing hearing assessment with their PCP in the next 6 months. Likelihood will be assessed on an 11-point visual analogue scale (VAS). Score range: 0 to 10 (0 = not likely, 10 = very likely). Participants who have already discussed hearing assessment with their PCP will be assigned a score of 10.

Interventions

  • BEHAVIORAL Automated text message reminder

Trial Details

FieldValue
Enrollment Target 41 participants
Start Date 2022-10-17
Est. Completion 2023-10-25
Phase NA
Stanford University

1,744 total trials

What the finished NCT05438225 record still lists

NCT05438225 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 41 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (97% lower).

The record links to 0 conditions, and to 1 intervention - of which Automated text message reminder is the first listed.

NCT05438225 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT05438225 about?

NCT05438225 is a clinical study titled "Text Message Reminders for Hearing Healthcare". Many individuals with hearing loss do not receive adequate hearing healthcare. Given their close and long-term relationships with patients, primary care providers (PCPs) could play a vital role in improving access to hearing healthcare. Unfortunately, hearing loss is often underdiagnosed in primary ...

What is the current status of trial NCT05438225?

This trial is currently completed. It is a NA study. The enrollment target is 41 participants. The study started on 2022-10-17. Estimated completion is 2023-10-25.

What interventions are being tested in trial NCT05438225?

The interventions under investigation include: Automated text message reminder (BEHAVIORAL).

Who is sponsoring clinical trial NCT05438225?

This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT05438225's enrollment target sits among peer trials

41 1446th of 2000 higher than 554 of 2,000 other NA trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03449238 · 41 participants · Phase 1

    Pembrolizumab And Stereotactic Radiosurgery (Srs) Of Selected Brain Metastases In Breast Cancer Patients

  • NCT03900793 · 41 participants · Phase 1

    Losartan + Sunitinib in Treatment of Osteosarcoma

  • NCT04082520 · 41 participants · Phase 2

    Lutathera for the Treatment of Inoperable, Progressive Meningioma After External Beam Radiation Therapy

  • NCT04220190 · 41 participants · Phase 2

    RAPA-501 Therapy for ALS

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT05438225, the US trial registry maintained by the National Library of Medicine. NCT05438225 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.